A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 (PHYOX2)
Study Dates
Last Modified
Tags
Publisher
Abstract
This study was intended to generate new knowledge about the impact of Primary Hyperoxaluria (PH) on kidney function and characterize the clinical course for children with PH.
Funder(s)
Provenance
Description
This study was conducted in collaboration with Dicerna Pharmaceuticals to understand the characteristics, health care utilization, and outcomes of children with Primary Hyperoxaluria (PH), a rare genetic disorder characterized by the over-production of oxalate that manifests with complications of the kidneys. Three forms of PH (PH1, PH2, and PH3) posses similar clinical manifestations. The distinctions between the three forms were studied throughout this project. Regulatory authorities have not approved therapies for the treatment of patients with PH. This study was intended to generate new knowledge about the impact of PH on kidney function and characterize the clinical course for children with PH. This information will provide a better understanding of clinically relevant outcomes that could be assessed and improved in clinical trials of Nedosiran, a novel RNAi therapeutic that targets LDH-A expression in the liver.
The study identified pediatric patients with all types of PH in seven PEDSnet affiliate healthcare systems. These patients were then informed of the opportunity to participate in clinical trials conducted by Dicerna Pharmaceuticals, particularly PHYOX2, for Nedosiran, a synthetic ribonucleic acid interference (RNAi) drug that substantially reduces the activity of LDHA, a key enzyme in oxalate production in the liver. In addition, this study defined a clinical phenotype of children with PH by ascertaining their characteristics, clinical outcomes (e.g. kidney function, imaging findings), and health services utilization.
The cohort for this study included children with diagnosed PH. Children were first identified in the PEDSnet CDM by a centralized query based on SNOMED diagnosis codes. The medical records of each of those children were then reviewed by a chart reviewer at each of the PEDSnet institutions to confirm that the patient had a record of confirmatory genetic testing and to verify the PH type.
This study was made possible through funding from Dicerna Pharmaceuticals (United States).
Development Code
Vocabulary
Clinical Subjects Headings
Related Publications
Ching, CB, Dickinson K, Karafilidis J, et al. 2023. “The real world experience of pediatric primary hyperoxaluria patients in the PEDSnet clinical research network.” Eur J Pediatr 182, 4027-4036. DOI: 10.1007/s00431-023-05077-y
Tasian G, Dickinson K, Karafilidis J, Marchesani N, Antunes N, Razzaghi H, et al. October 2022. “Diagnostic Code-Based Screening for Identifying Children with Primary Hyperoxaluria.” Journal of Urology. 208(4):898-905.
DOI: 10.1097/JU.0000000000002863
Creative Commons license
